18 February 2026
Asahi Kasei Pharma Advances AK1960 to Phase I for Refractory Diseases
AK1960, an ETA receptor antagonist, enters Phase I trials for refractory diseases, leveraging Alchemedicine's HiSAP™ platform and partnerships with Calliditas and Veloxis.